Highlights

  • Clarity Pharmaceuticals (ASX:CU6) reported an FY26 loss of AUD 107.24mn.
  • Liquid assets reached AUD 178.3mn at 30 June 2026, including term deposits.
  • SECuRE reached the recruitment target for its 16-participant main expansion group.
  • The CLARIFY and AMPLIFY Phase III diagnostic programs continued in 2026.

Clarity Pharmaceuticals Limited develops copper-based radiopharmaceuticals for imaging and treating cancer, with clinical programs focused on prostate cancer and other tumours. On 26 October 2026, Clarity Pharmaceuticals (ASX:CU6) was quoted at AUD 1.575, up 0.32% for the session at the time of the quotation. Its recent developments include completion of recruitment for the main expansion group in the SECuRE study, alongside FY26 financial results reflecting increased clinical development expenditure.

Company Business

Clarity Pharmaceuticals (ASX:CU6) is a clinical-stage business using its proprietary SAR technology to attach radioactive copper isotopes to targeting molecules. Copper-64 is employed for diagnostic positron emission tomography imaging, while copper-67 is being investigated for targeted therapy. The approach is intended to identify relevant tumours and, in selected programs, deliver radiation to diseased tissue.

Its SAR-bisPSMA program targets prostate-specific membrane antigen in prostate cancer. Diagnostic development includes the Phase III CLARIFY and AMPLIFY studies, while the SECuRE program examines copper-67 SAR-bisPSMA as a treatment for metastatic castration-resistant prostate cancer. Other programs include SARTATE for neuroendocrine tumours and SAR-Bombesin for cancers expressing a different target. Clinical activity spans the United States and Australia.

Recent Development

On 8 October 2026, Clarity Pharmaceuticals (ASX:CU6) announced that 16 participants had been enrolled in the main group of the SECuRE Phase I/IIa cohort expansion. These patients are being evaluated for safety and efficacy with up to six cycles of 8 GBq copper-67 SAR-bisPSMA. Recruitment continued in a separate arm combining the investigational product with enzalutamide.

The expansion program is designed to study 24 patients in the relevant treatment setting, divided between combination and non-combination groups. In an earlier August assessment involving 19 participants at the 8 GBq dose level, 74% of evaluable participants achieved a prostate-specific antigen reduction of at least 25%, while 63% reached a reduction of at least 50%. Among 16 radiographically evaluable patients, 81% demonstrated disease control. These were early clinical observations rather than outcomes of a completed registrational study.

The company also continued preparations for diagnostic trial readouts in its prostate cancer portfolio. CLARIFY and AMPLIFY are Phase III studies using copper-64 SAR-bisPSMA in different diagnostic settings. The timing and interpretation of future data remain dependent on trial completion, data review and regulatory requirements.

Financial Performance and Sector Context

For FY26, Clarity Pharmaceuticals (ASX:CU6) reported a net loss of AUD 107.24mn, compared with AUD 64.30mn in FY25. Research and development expenses increased to AUD 91.08mn from AUD 66.88mn, as clinical trials and commercial-readiness activities expanded. Corporate and commercialisation expenses were AUD 27.83mn, compared with AUD 11.68mn a year earlier.

Finance income reached AUD 8.00mn, while the research and development tax incentive recognised was AUD 10.53mn. The group recorded net operating cash outflow of AUD 92.55mn, compared with AUD 54.77mn in FY25. The reported finance income is distinct from sales of approved radiopharmaceutical products; the company remained pre-commercial.

At 30 June 2026, cash and cash equivalents amounted to AUD 57.21mn and term deposits to AUD 121.05mn, together representing approximately AUD 178.3mn in liquid assets. Net assets were AUD 186.11mn. The clinical radiopharmaceutical sector involves substantial expenditure on trial recruitment, isotope supply, manufacturing validation and regulatory submissions before product revenue can commence.

Risks to Consider

Clarity Pharmaceuticals (ASX:CU6) faces uncertainty over clinical efficacy, patient recruitment, adverse events and whether trial results meet regulatory standards. Expanded studies and manufacturing preparations can increase cash consumption. Copper-isotope production, shipping logistics and specialised manufacturing capacity are operational dependencies. Additional capital could be required beyond existing forecasts, and future fundraisings may dilute existing shareholders. Commercial sales also depend on product approval and market access.

What to Watch Next

For Clarity Pharmaceuticals (ASX:CU6), forthcoming milestones include further SECuRE follow-up, recruitment in the enzalutamide combination arm and subsequent clinical data releases. Progress in CLARIFY and AMPLIFY, along with any regulatory discussions concerning diagnostic registration, will be relevant. Quarterly cash-flow statements will indicate the pace of spending relative to liquid assets. The company has scheduled its annual general meeting for 25 November 2026.

Key Insights

Clarity's FY26 results reflect higher research spending and cash use, accompanied by increased liquid assets at year-end. The latest SECuRE update establishes recruitment progress in a defined patient group, while later-stage imaging studies remain central to its development program. Clinical evidence, regulatory steps, manufacturing readiness and funding remain the principal measurable factors in the next reporting periods.